News | September 08, 2010

IVUS-Guided Bifurcation Stenting Helps Improve Outcomes


September 8. 2010 – Intravascular ultrasound (IVUS)-guided bifurcation stenting significantly reduced the four-year mortality in patients as compared to conventional angiographically guided stenting, according to a recent study.

The study, supported in part by the Cardiovascular Research Foundation, was conducted in Seoul, South Korea and published in the Sept. 1 issue of the American Journal of Cardiology (volume 106, issue 5 , pages 612-618, Sept. 1, 2010).

In addition, researchers found IVUS guidance reduced the development of very late stent thrombosis in patients receiving drug-eluting stents (DES).

Stenting for bifurcation lesions is challenging and the effect of IVUS guidance on long-term outcomes has not been evaluated. Researchers assessed the long-term outcomes of IVUS-guided stenting in bifurcation lesions in 758 patients with de novo nonleft main coronary bifurcation lesions. They compared adverse outcomes (i.e., death, stent thrombosis, and target lesion revascularization) within four years, after adjustment using a multivariate Cox proportional hazard model and propensity scoring.

IVUS-guided stenting significantly reduced the long-term all-cause mortality in the total population and in the patients receiving DESs, but not in the patients receiving bare metal stents. IVUS-guided stenting had no effect on the rate of stent thrombosis or target lesion revascularization. In patients receiving DESs, however, IVUS guidance reduced the development of very late stent thrombosis (0.4 vs. 2.8 percent).

For more information: www.ajconline.org


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 β€”Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 β€” Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 β€” CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now